Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy

HIV-specific T-cell responses reflect substantive in vivo interactions with antigen despite long-term therapy

(2021) Eva M. Stevenson et al.   JCI Insight

Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study

(2021) Thomas A Rasmussen et al.   CLINICAL INFECTIOUS DISEASES

Combination Immune Checkpoint Blockade to Reverse HIV Latency

(2020) Renée M. Van der Sluis et al.   JOURNAL OF IMMUNOLOGY

Multi-stakeholder consensus on a target product profile for an HIV cure

(2020) Sharon R Lewin et al.   Lancet HIV

Roles, function and relevance of LAG3 in HIV infection

(2019) Colin G. Graydon et al.   PLoS Pathogens

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals

(2019) Rémi Fromentin et al.   Nature Communications

PD-1+ AND TIGIT+ CD4 T CELLS ARE ASSOCAITED WITH CORONARY ARTERY CALCIUM PROGRESSION IN HIV-INFECTED TREATED ADULTS

(2019) Scott Bowler et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

(2019) Anand Rotte   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study

(2019) Edward Gane et al.   JOURNAL OF HEPATOLOGY

On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment

(2019) Grazia R. Tundo et al.   CHEMOTHERAPY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer

(2019) Guoping Ding et al.   BMC CANCER

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

(2019) Yunlong Zhao et al.   IMMUNITY

Why and where an HIV cure is needed and how it might be achieved

(2019) Thumbi Ndung’u et al.   NATURE

HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy

(2019) Yinyan Xu et al.   Molecular Therapy-Methods & Clinical Development

Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection

(2018) E P Scully et al.   ANNALS OF ONCOLOGY

Mechanistic peculiarities of activation-induced mobilization of cytotoxic effector proteins in human T cells

(2018) Marcus Lettau et al.   INTERNATIONAL IMMUNOLOGY

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction

(2018) Bhagyashree Bhagwat et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells

(2018) Filippos Porichis et al.   JOURNAL OF IMMUNOLOGY

Barriers and strategies to achieve a cure for HIV

(2018) Matthew C Pitman et al.   Lancet HIV

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Contrasting roles of the PD-1 signaling pathway in dendritic cell-mediated induction and regulation of HIV-1-specific effector T cell functions

(2018) Tatiana M. Garcia-Bates et al.   JOURNAL OF VIROLOGY

Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells

(2018) Suresh Pallikkuth et al.   PLoS One

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

(2017) Cynthia L. Gay et al.   JOURNAL OF INFECTIOUS DISEASES

Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection

(2017) Jeffrey E. Teigler et al.   JOURNAL OF VIROLOGY

Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals

(2017) Johanna Tauriainen et al.   Scientific Reports

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1

(2016) Sabrina Jutz et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

(2016) Mark J. Selby et al.   PLoS One

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

(2016) Glen M. Chew et al.   PLoS Pathogens

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART

(2016) Rémi Fromentin et al.   PLoS Pathogens

Exposure of Human CD4 T Cells to IL-12 Results in Enhanced TCR-Induced Cytokine Production, Altered TCR Signaling, and Increased Oxidative Metabolism

(2016) Aldo Vacaflores et al.   PLoS One

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

(2015) Gregory M. Laird et al.   JOURNAL OF CLINICAL INVESTIGATION

The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects

(2015) Xiaoling Tian et al.   JOURNAL OF IMMUNOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway

(2015) Brian Tomkowicz et al.   PLoS One

Ikaros Imposes a Barrier to CD8+ T Cell Differentiation by Restricting Autocrine IL-2 Production

(2014) S. O'Brien et al.   JOURNAL OF IMMUNOLOGY

Differential Impact of PD-1 and/or Interleukin-10 Blockade on HIV-1-Specific CD4 T Cell and Antigen-Presenting Cell Functions

(2013) F. Porichis et al.   JOURNAL OF VIROLOGY

Molecular signatures of T-cell inhibition in HIV-1 infection

(2013) Marie Larsson et al.   Retrovirology

The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells

(2013) Anna Schurich et al.   PLoS Pathogens

Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection

(2012) L. Trautmann et al.   BLOOD

Down-regulation of interleukin-2 production by CD4+ T cells expressing TIM-3 through suppression of NFAT dephosphorylation and AP-1 transcription

(2012) Mi Jin Lee et al.   IMMUNOBIOLOGY

Responsiveness of HIV-specific CD4 T cells to PD-1 blockade

(2011) F. Porichis et al.   BLOOD

Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection

(2011) T. Yamamoto et al.   BLOOD

Regulation of Virus-Specific CD4+ T Cell Function by Multiple Costimulatory Receptors during Chronic HIV Infection

(2010) A. Kassu et al.   JOURNAL OF IMMUNOLOGY

Strong Ability of Nef-Specific CD4+ Cytotoxic T Cells To Suppress Human Immunodeficiency Virus Type 1 (HIV-1) Replication in HIV-1-Infected CD4+ T Cells and Macrophages

(2009) N. Zheng et al.   JOURNAL OF VIROLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Distinct requirements for activation-induced cell surface expression of preformed Fas/CD95 ligand and cytolytic granule markers in T cells

(2008) D Kassahn et al.   CELL DEATH AND DIFFERENTIATION

TIMs: central regulators of immune responses: Figure 1.

(2008) David A. Hafler et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

(2008) R. Brad Jones et al.   JOURNAL OF EXPERIMENTAL MEDICINE